
These 4,500-year-old rattles may be among the world's oldest toys
Clay rattles made in Syria about 4,500 years ago were designed to 'amuse and calm' infants, according to a new study. But some archaeologists think they were used in rituals to dispel evil spirits, or that they might have served both purposes.
'They have little handles that are too small for me, and I have quite small hands,' says archaeologist Mette Marie Hald from the National Museum of Denmark in Copenhagen. 'They are for infants or toddlers.'
In the new study published in the journal Childhood in the Past, Hald and her co-authors describe artifacts kept by the museum after excavations of an ancient mound in Hama in Syria in the 1930s. The possible playthings are among the oldest toys in the archaeological record.
(Who made these unusual ancient 'puppets'—and left them atop a pyramid?) Early excavations
Many of the artifacts ended up in museums throughout the Middle East, including Syria's National Museum of Damascus. But the expedition members took some back to Denmark, where they were placed in storage until Hald and her colleagues re-examined them.
The new analysis has established that at least 21 of the clay fragments come from rattles made between about 4,500 and 4,000 years ago, during the Early Bronze Age, when Hama was one of several ancient city-states in the region.
Hald says part of one rattle had been misidentified as a 'sieve' because it contained holes; and the hollow handle of another was mislabeled as 'piping.' Examples of handles and bodies from the Hama rattle assemblage are superimposed over the outline of a complete rattle from another site in Syria called Al-Zalaqiyat. Photoillustration by G. Mouamar, the National Museum of Denmark Bronze Age rattles or wards against evil?
The analysis shows the fragments are almost identical in style and size to an unbroken rattle found at an ancient cemetery a few miles north of Hama, named Al-Zalaqiyat, and to rattles from other Early Bronze Age sites now held at the museum in Damascus.
Those rattles were filled with pebbles or small clay pellets, to make a noise when they were shaken—similar to some modern baby toys—and so the authors suggest they were designed for small children to play with.
Some archaeologists have proposed that the rattles were 'apotropaic'—meaning the noise they made was designed to ward off evil spirits—or that they were used as musical instruments.
But the study's lead author, archaeologist Georges Mouamar of the National Museum of Denmark and the French research agency CNRS, carried out experiments with the rattle from Al-Zalaqiyat and determined it was too small to have made much noise.
'It just made a tiny little sound,' Hald says. 'It wouldn't have been very entertaining as a musical instrument.'
The Hama fragments were also found in what had been a domestic neighborhood, rather than a temple or a burial ground; and this strengthened the idea they were used by children, Hald says.
The analysis also determined that the Hama fragments were made from the same distinctive mix of clays as commercial pottery from the ancient city—implying the rattles were made by professional potters for sale at street markets to parents.
The Hama rattles seem well-finished, with intricate designs in pottery glaze that support the idea they were made by professionals, Hald says.
Hama was a regional center during the Early Bronze Age, and so the rattles may have been mass produced there for sale elsewhere.
Other types of rattles have been found in other parts of Syria and the Middle East—rattles shaped like animals, for example, are often found in northern Syria—and so it is likely local potters made them in locally popular styles, she says. Fragments of 4500-year-old baby rattles match the chemical makeup of other ceramic housewares from Hama. Photograph by John Fhær Engedal Nissen, the National Museum of Denmark
The new study has stirred debate among experts over whether the Hama rattles and others like them served a ritual or playful purpose.
Archaeologist Elynn Gorris of Belgium's University of Louvain, who was not involved in the study, is concerned that the Hama rattles, while small, would have been too large and heavy for babies to hold. But she allows that they would have been suitable for toddlers.
Gorris notes that similar rattles have been found at archaeological sites in the Americas—including a similar rattle from California that may be up to 1,000 years old—where evidence indicates they were used traditionally in rituals and for making music, as they still are today.
But 'this is not about wrong or right—this is an inclusive story,' she says. 'These could have been used by toddlers, but that doesn't exclude the fact that they could have been percussion instruments to keep rhythm for adults, for lullabies or for ritual songs.'
Archaeologist Kristine Garroway, a professor at Hebrew Union College-Jewish Institute of Religion in Los Angeles who has studied clay rattles from the ancient Levant, is 'very convinced' by the study's findings. But she also thinks the rattles may have had a 'dual use,' first as apotropaic devices to scare evil spirits from homes and then as noisemakers to amuse small children. 'These could have been used in multiple different ways,' she says.
(What can we learn from a Bronze Age lunchbox?)
If the rattles are toys, then they are some of the earliest that survive—other contenders include a 5000-year-old chariot from Turkey and a 4000-year-old stone head, possibly from a doll, from an Italian island.
The fact the researchers are thinking about ancient children is important, notes Garroway: 'Children get overlooked in the archaeological record, [so] to even stop and think that children could have been using these objects is amazing.'
For Hald, all the evidence indicates the Hama rattles were designed to keep small children entertained. 'Parents in the past loved their children, just as we do today,' she says. 'But perhaps parents also needed to distract their children now and then so that they could have a bit of peace and quiet to themselves. Today, we use screens, back then it was rattles.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 hours ago
- Business Wire
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).


Boston Globe
a day ago
- Boston Globe
Étienne-Émile Baulieu, ‘father of the abortion pill,' dies at 98
'I do not like abortion,' Dr. Baulieu wrote in his 1991 book, 'The Abortion Pill,' written with journalist Mort Rosenblum. 'But neither do I believe that women should be deprived of their most fundamental rights.' Dr. Baulieu, who specialized in hormone research at a French government lab, had already by the 1970s made one breakthrough discovery relating to a hormone and certain health risks. He next sought to explore new birth control methods, nearly two decades after the first oral contraceptive, Enovid, was approved for use in the United States in 1960. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Dr. Baulieu narrowed his research to sex hormones, particularly progesterone, which is essential to pregnancy because it prepares the uterus for a newly fertilized egg. Advertisement He knew that the French drug company Roussel-Uclaf — where he was a consultant on drug development — would not invest in a sex-hormone drug linked to birth control. Instead, he nudged the company to support work on a molecular compound to block cortisone, a hormone involved in blood sugar regulation, metabolism, and suppressing inflammation. Advertisement The key for Dr. Baulieu was that cortisone had a chemical structure similar to that of progesterone. Dr. Baulieu suggested that a cortisone-blocking agent, called an anti-glucocorticoid, could be useful for the treatment of burns, wounds, and glaucoma. Privately, he also hoped it would act as an anti-progesterone and prove effective in terminating early pregnancies without the need for surgery. In 1980, Roussel-Uclaf chemist Georges Teutsch synthesized RU-38486, or the 38,486th compound created at the company's labs. The compound — its molecular name shortened to RU-486 — was found to block the function of progesterone and cortisone, as Dr. Baulieu anticipated. He ultimately persuaded the company to pursue human abortion trials. He first, however, had to make the case that RU-486 was safe. Toxicity tests had caused three monkeys to become so ill that they had to be euthanized. Dr. Baulieu argued that the drug was working as it should, but that the monkeys were given doses that were too high. He told the Observer, a British newspaper, that he had 'rescued RU-486 from oblivion.' After clinical trials — first in Switzerland, then in Hungary and Sweden — Roussel-Uclaf received French approval in 1988 to market the drug to end pregnancies up to 10 weeks after a missed menstrual period. RU-486 (whose generic name is mifepristone and which was marketed as mifeprex in the United States) is followed within 48 hours by a drug known as misoprostol to induce uterine contractions. The two drugs are supposed to be prescribed by a physician and can be taken at home without medical supervision. RU-486 was the product of a team effort, but Dr. Baulieu was seen as the drug's key architect and advocate. He became known as 'the father of the abortion pill' and was a reviled target of antiabortion activists and others. Advertisement The Vatican in 1997 denounced RU-486 as 'the pill of Cain: the monster that cynically kills its brothers.' In Canada, a billboard once displayed Dr. Baulieu's picture and the words, 'Wanted for genocide.' In 1988, he was protected by bodyguards during a trip to the United States. But he also said he received messages of thanks from women who were able to end their pregnancies without a surgical procedure. In France, the antiabortion sentiment was so strong that Roussel-Uclaf halted production of the drug soon after it was approved for distribution. Protests raged outside Roussel-Uclaf headquarters in Paris. 'You are turning the uterus into a crematory oven,' demonstrators yelled, alluding to the production of poison gas for Nazi Germany by a predecessor of Hoechst, the holding company that owned Roussel-Uclaf. With drug production on hold, Dr. Baulieu traveled to Brazil for a medical conference that turned into a 'pep rally' for RU-486, the New York Times reported. By the end of the conference, the drug was reinstated by Roussel-Uclaf. Claude Évin, then health minister of France, had declared that RU-486 was 'the moral property of women.' 'Before we left Rio,' Dr. Baulieu wrote in his book, 'we opened the champagne.' The FDA approved mifepristone (pronounced mi-fuh-PRI-stone) in 2000, more than a decade after it became available in China and in Russia and other parts of Europe. (U.S. research into the drug as an abortion medication had been banned, but it was studied as a treatment for hormonal disorders including Cushing's syndrome.) The drug's delay in the United States came from fear of boycotts against Hoechst and a heavily politicized climate around the approval process. Advertisement Since Roe v. Wade and its protection of U.S. abortion rights were overturned in 2022, mifepristone has been at the center of legal questions over whether antiabortion states can block the Postal Service from delivering the drug. Mifepristone is used in more than 60 percent of abortions in the United States, according to the Guttmacher Institute, a research and policy group focusing on reproductive health. 'Ideology and machismo, alas, weigh more heavily than rationality and scientific proof,' Dr. Baulieu told the New Yorker in 2022. 'A method that makes the termination of pregnancy less physically traumatic for women and less risky to their health has always been rejected by pro-lifers: What they really seek is to harm and punish women.' He often recounted an incident from his medical residency in Paris in the 1950s. A surgeon, scraping the uterus of a woman who had self-administered an abortion, refused to render her unconscious with general anesthesia, remarking that it would 'teach her a lesson she will remember,' he said. As an authority on reproduction, Dr. Baulieu became part of a government committee that helped change French law in 1967 to allow the birth control pill. Later, during a visit to India in 1970, Dr. Baulieu was shaken when a woman begging for money shoved the body of her dead child at him. 'During that trip,' Dr. Baulieu recalled, 'I decided to aim my life's work toward finding some way to ease this sort of suffering.'

2 days ago
French scientist Etienne-Emile Baulieu, inventor of the abortion pill, dies at 98
ROME -- French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement. Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones. 'His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives,' the Institut Baulieu said in the statement posted on its website. Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name 'Émile Baulieu' when he joined the French Resistance against the Nazi occupation at the age of 15. An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997. He is best known for his development, in 1982, of RU 486, the so-called 'abortion pill' that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety. The Institut Baulieu said it was 'a non-invasive method, less aggressive and less delayed than surgery,' noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights. 'Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method,' the institute added. Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids -- or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals. In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's. Honored with the grand crosses of the Légion d'honneur (legion of honor) and the Ordre national du Mérite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004. He was a member of the national advisory committee on life sciences and health (1996-2002) and received numerous awards, both in France and abroad. French President Emmanuel Macron paid tribute to Baulieu in a post on X, calling him 'a beacon of courage' and 'a progressive mind who enabled women to win their freedom.' 'Few French people have changed the world to such an extent,' he added. After the death of his first wife, Yolande Compagnon, he remarried, to Simone Harari Baulieu. He is survived by three children, eight grandchildren and nine great-grandchildren, his institute said.